Should All Stent Patients Have Prolonged Dual Antiplatelet Therapy?  by Kirtane, Ajay J. & King, Spencer B.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 6 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 5 . 0 4 . 0 0 1EDITOR’S PAGEFrom the *Herbert and Sandi Feinberg Interventional C
Heart Valve Center at Columbia University Medical Cen
Presbyterian Hospital and the Cardiovascular Research
New York, New York.Should All Stent Patients
Have Prolonged Dual
Antiplatelet Therapy?
Ajay J. Kirtane, MD, SM, FACC,*
Spencer B. King III, MD, MACC, Editor-in-Chief,
JACC: Cardiovascular InterventionsT he current standard of dual antiplatelet ther-apy (DAPT) consisting of oral aspirin plus aninhibitor of the P2Y12 receptor following cor-
onary stent implantation was established in several
landmark studies conducted in the 1990s (1,2). Clin-
ical trials conducted with bare-metal stents (BMS)
demonstrated that DAPT was highly effective at pre-
venting early stent thrombosis (ST), which was
alarmingly common in the early days of coronary
stenting. This DAPT regimen, in conjunction with
higher-pressure stent deployment, was critically
important in supporting the more widespread use of
coronary stents as a default therapy for percutaneous
coronary intervention, particularly given that ST
occurring within the ﬁrst 30 days following stent
implantation was associated with myocardial infarc-
tion (MI) in w75% of patients, resulting in death in
w20% of patients (3).
Although implementation of DAPT can, therefore,
be considered “obligatory” to prevent ST immediately
following stent implantation, the ideal duration of
DAPT has been a moving target. With the introduc-
tion of drug-eluting stents (DES) came the recognition
that ST was not conﬁned to the ﬁrst 30 days following
stent implantation. Indeed, even the notion that ST
following BMS was conﬁned to the early period was a
fallacy, with observational data demonstrating ST
events years after the initial implant (4). Despite
the fact that early DES devices were approved on
durations of DAPT ranging from 3 to 6 months, withardiology and
ter/New York-
Foundation,pooled analyses of randomized trials demonstrating
no excess in ST compared with BMS comparators out
to 5 years (5), both the U.S. Food and Drug Adminis-
tration as well as society guidelines recommended
extension of DAPT to at least 1 year following DES
implantation in patients at low risk for bleeding (6).
This was in part due to observational data demon-
strating lower rates of late ST with continuance of
DAPT beyond the durations prescribed in approval
studies (7).
In light of concerns regarding the robustness of
existing datasets when apprehensions of late ST with
DES reached their height in late 2006, the U.S. Food
and Drug Administration mandated further study of
prolonged DAPT as a means of mitigating ST risk. In a
formidable achievement of trial design and execu-
tion, the DAPT trial began: speciﬁcally powered to
examine the effect of extended duration DAPT
(30 months vs. 12 months) upon the occurrence of
very late ST. Beyond ST prevention, the DAPT
trial also aimed to study whether prolonged DAPT
could possibly also lead to passivation of ischemic
events relating to generalized atherothrombosis in
stented patients with coronary artery disease. Several
prior studies in broader patient populations had
previously aimed to assess this potential beneﬁt of
DAPT, but had produced mixed results; although
some anti-ischemic efﬁcacy could be demonstrated
(particularly in higher-risk subgroups), bleeding was
increased (8).
The DAPT trial ultimately demonstrated in 9,961
randomized patients that prolonged DAPT was asso-
ciated with reductions in late ST, late MI, and also late
composite ischemic events (death, MI, or stroke), but
with an increase in bleeding events (9). Notably,
although MI related to ST was reduced by prolonged
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874DAPT, more than one-half of the overall reduction
in MI was independent of ST, supporting the notion
that DAPT has generalized anti-ischemic beneﬁts
in stented patients. These ﬁndings are very consis-
tent with those of the recently reported PEGASUS-
TIMI 54 (Prevention of Cardiovascular Events in Pa-
tients with Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin–
Thrombolysis in Myocardial Infarction 54) trial, which
demonstrated that prolonged DAPT with aspirin and
ticagrelor reduced ischemic events in stabilized pa-
tients >1 year after an MI, but with a signiﬁcant in-
crease in Thrombolysis In Myocardial Infarction
major bleeding (10).
So, what is the clinician to make of these results? Is
prolonged DAPT the new gold standard? In our mind—
and despite the several positive effects of prolonged
DAPT previously outlined—the simple answer re-
mains, “Not for most patients.” Our rationale for this
statement stems from further analyses of the absolute
magnitude of ischemic reduction seen within the
speciﬁc patients enrolled in the DAPT trial as well as a
recognition of the importance of bleeding complica-
tions to patient satisfaction and outcomes.
The DAPT trial enrolled a selected group of patients
who were event-free at 12 months (i.e., they had
already successfully tolerated 12 months of DAPT
prior to enrollment without events). Moreover, of
these patients, only 47% of DES-treated patients
received stents currently utilized in clinical practice
(newer-generation DES). It should be noted that the
relative magnitude of the treatment effect of pro-
longed DAPT (relating to both ST reduction and MI
reduction) was consistent, irrespective of stent type.
However, because the overall incidence of ST is
signiﬁcantly lower with newer-generation stents, the
number of events prevented with prolonged DAPT in
newer-generation stent patients in the trial was far
less (only 10 ST events prevented vs. 35 among other
stent types). Stated another way, although prolonged
DAPT did reduce the incidence of ST from 0.7% to
0.3% even with newer-generation stents, one would
have to treat 250 such patients with prolonged DAPT
to prevent 1 ST event occurring a year after stent im-
plantation. This ﬁnding is even more relevant given
the signiﬁcantly better prognosis (nearly one-half the
mortality) of having a late ST event compared with an
early ST event (11). Even the overall reduction in MI
events within the DAPT trial is modest on an absolute
scale, with 2 events prevented per 100 patients
treated with prolonged DAPT in the overall study
cohort (only 1.1 event prevented per 100 newer-
generation stent patients treated with prolonged
DAPT).Despite the overall anti-ischemic beneﬁts of pro-
longed DAPT, overall mortality in the trial trended
higher among patients treated with prolonged DAPT
(2.0% vs. 1.5%, p ¼ 0.052). Perhaps this was due to
play of chance, especially given that the study was
not powered to detect differences in overall mortal-
ity. Nonetheless, the ﬁnding of a trend toward
increased all-cause mortality—driven by an increase
in noncardiovascular mortality—within the DAPT trial
is directionally consistent with a that of a number of
other prolonged DAPT studies in DES-treated patients
(12). Even when expanded to a broader population
and much larger sample of patients with coronary
artery disease (almost 70,000 patients with 139,000
patient-years of follow-up including both stent trials
as well as secondary prevention trials), there is not a
trend toward an overall mortality beneﬁt with pro-
longed duration DAPT, with a summary estimate
ﬁrmly neutral (13). The absence of a beneﬁcial all-
cause mortality signal (a result that will not change
with the inclusion of 21,162 additional patients from
PEGASUS-TIMI 54) should give us pause before
advocating prolonged DAPT for all. If clinically
important ischemic complications are markedly low-
ered by prolonged DAPT, then why are we not seeing
even a hint of a beneﬁt in terms of mortality with this
approach?
Weighing strongly against the ischemic protection
provided by prolonged DAPT is a continual exposure
to bleeding risk, which itself is prognostically impor-
tant and associated with increased mortality. In the
DAPT trial, moderate-severe bleeding was increased
with prolonged DAPT as measured by several vali-
dated bleeding scales. This increase in bleeding has
been a consistent ﬁnding in other studies of prolonged
DAPT (12). Although the clinical events committee in
the DAPT trial did not adjudicate a difference in fatal
bleeding (bleeding directly resulting in a death), in
more detailed analyses of bleeding events, there were
strong trends toward an increase in both bleeding-
related death (11 events vs. 3 events, p ¼ 0.057) and
trauma-related death (9 events vs. 2 events, p ¼ 0.07)
with prolonged DAPT. Add to this the real perception
by many patients of what clinical trials often dismis-
sively term “nuisance bleeding” (such as frequent
bruises and persistent bleeding from nicks/cuts) (14),
combined with the potential effect of bleeding upon
patient behavior (such as medication discontinua-
tion), and the bleeding-related side effects of pro-
longed DAPT are not to be trivialized. Another
important facet of the bleeding-ischemia tradeoff
additionally relates to the perspective of the patient
and treating physician: ischemic events may be
perceived as part of the natural history of disease,
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875whereas bleeding events have been caused by pre-
scribed medications. Although some patients may be
willing to accept signiﬁcant up-front bleeding risks
to avoid an MI, we need to be very clear and honest
about the types of MI prevented by prolonged DAPT
when speaking with our patients. For example, when
patients participating in shared decision-making
are asked about theoretically preventing a future MI,
are they visualizing the prevention of “massive” heart
attacks or troponin elevations instead?
Ultimately, the decision of whether to prescribe
prolonged duration DAPT hinges upon the overall
projected risks of ischemia and bleeding within an
individual patient. Prolonged DAPT clearly reduces
the risks of both late stent- and nonstent-related
ischemic events, but the iatrogenic bleeding risk
incurred is real, and ought not to be minimized in our
zeal to prevent cardiovascular events. Moreover, the
relative signiﬁcance of these very late ischemic
events may be appreciably less than when the same
events (e.g., ST) occur within the ﬁrst few monthsafter stent implantation. As such, the bleeding risks
of prolonged DAPT combined with the neutral-
negative effect of prolonged DAPT on all-cause mor-
tality should give us pause before widely advocating
prolonged DAPT to all stent patients. Among certain
groups for whom the absolute risk of ischemic events
is greatest (e.g., those with recurrent ischemic events,
those with true acute coronary syndromes, or those
with early-generation DES), we ought to strongly
consider extension of DAPT. But for the majority of
stent patients—particularly for unselected stable
patients treated with current generation devices—to
broadly recommend prolonged DAPT seems of
limited overall utility.
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